Last reviewed · How we verify

buspirone+alprazolam — Competitive Intelligence Brief

buspirone+alprazolam (buspirone+alprazolam) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anxiolytic combination (azapirone + benzodiazepine). Area: Psychiatry / Neurology.

marketed Anxiolytic combination (azapirone + benzodiazepine) 5-HT1A receptor (buspirone); GABA-A receptor (alprazolam) Psychiatry / Neurology Small molecule Live · refreshed every 30 min

Target snapshot

buspirone+alprazolam (buspirone+alprazolam) — Seoul National University Hospital. This combination pairs a serotonin 5-HT1A receptor agonist (buspirone) with a benzodiazepine GABA-A receptor agonist (alprazolam) to enhance anxiolytic effects through dual pathways.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
buspirone+alprazolam TARGET buspirone+alprazolam Seoul National University Hospital marketed Anxiolytic combination (azapirone + benzodiazepine) 5-HT1A receptor (buspirone); GABA-A receptor (alprazolam)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anxiolytic combination (azapirone + benzodiazepine) class)

  1. Seoul National University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). buspirone+alprazolam — Competitive Intelligence Brief. https://druglandscape.com/ci/buspirone-alprazolam. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: